Supplemental material
Open access
5,929
Views
2
CrossRef citations to date
0
Altmetric
Article
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial
Carsten Flohra Department of Paediatric Dermatology, St John’s Institute of Dermatology, Guy’s & St Thomas’ NHS Foundation Trust and King’s College London, UKView further author information
, Michael J. Corkb Department of Infection, Immunity and Cardiovascular Disease, Sheffield Dermatology Research, University of Sheffield and Sheffield Children’s Hospital, Sheffield, UKView further author information
, Michael R. Ardern-Jonesc Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK;d Department of Dermatology, Southampton University Hospitals NHS Foundation Trust, Southampton, UKView further author information
, Lawrence F. Eichenfielde Departments of Dermatology and Pediatrics, UC San Diego and Rady Children’s Hospital–San Diego, San Diego, CA, USAView further author information
, Sébastien Barbarotf Department of Dermatology, CHU Nantes-Hôtel Dieu, Nantes, FranceView further author information
, Claire Feeneyg Pfizer Ltd., Tadworth, Surrey, UKView further author information
, Ricardo Rojoh Pfizer Inc., Groton, CT, USAView further author information
, Irina Lazariciui Pfizer Inc., New York, NY, USAView further author information
& John Nesnasg Pfizer Ltd., Tadworth, Surrey, UKCorrespondence[email protected]
View further author information
show allView further author information
Article: 2200866
|
Received 15 Nov 2022, Accepted 01 Mar 2023, Published online: 27 Apr 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.